Clinical trials for pediatric MS should be prioritized to test only one or two of the most promising agents - Commentary

Rogier Hintzen

Research output: Contribution to journal › Article › Academic

2 Citations (Scopus)

Access to Document

@article{f469100a28d145f6b22017feb8bfcd43,

title = "Clinical trials for pediatric MS should be prioritized to test only one or two of the most promising agents - Commentary",

author = "Rogier Hintzen",

year = "2016",

doi = "10.1177/1352458516661240",

language = "Undefined/Unknown",

volume = "22",

pages = "1653--1654",

journal = "Multiple Sclerosis Journal",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "13",

}

TY - JOUR

T1 - Clinical trials for pediatric MS should be prioritized to test only one or two of the most promising agents - Commentary

AU - Hintzen, Rogier

PY - 2016

Y1 - 2016

U2 - 10.1177/1352458516661240

DO - 10.1177/1352458516661240

M3 - Article

VL - 22

SP - 1653

EP - 1654

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

SN - 1352-4585

IS - 13

ER -